Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

Duration-adjusted analyses showed 420.4 adverse events (AEs)/100 patient-years (100PY), 8.5 serious AEs/100PY, 27 (1.8%) treatment discontinuations due to AEs, and no deaths; most common AEs (preferred term): nasopharyngitis (20.5%), upper respiratory tract infection (9.5%), exacerbation of AD (8.2%...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2017-02, Vol.139 (2), p.AB381-AB381
Hauptverfasser: Deleuran, Mette, Prof, Thaçi, Diamant, Prof, Beck, Lisa A., Prof, Forman, Seth, Dr, Soong, Weily, Dr, Hussain, Iftikhar, Dr, Bissonnette, Robert, Dr, Bouaziz, Jean-David, Dr, Gelfand, Joel, Prof, Sher, Lawrence, Dr, Chen, Zhen, Dr, Akinlade, Bolanle, Dr, Gadkari, Abhijit, Dr, Eckert, Laurent, Dr, Graham, Neil M.H., Dr, Pirozzi, Gianluca, Dr, Ardeleanu, Marius, Dr
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Dermatitis
FDA approval
Pruritus
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Duration-adjusted analyses showed 420.4 adverse events (AEs)/100 patient-years (100PY), 8.5 serious AEs/100PY, 27 (1.8%) treatment discontinuations due to AEs, and no deaths; most common AEs (preferred term): nasopharyngitis (20.5%), upper respiratory tract infection (9.5%), exacerbation of AD (8.2%); conjunctivitis AEs (all etiologies) occurred in 10.7% of patients.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2016.12.915